We recently compiled a list of the Why These 15 Stocks Are Skyrocketing in 2025. In this article, we are going to take a look at where Vir Biotechnology, Inc. (NASDAQ:VIR) stands against the other ...

Leerink Partners analyst Roanna Ruiz reiterated a Buy rating on Vir Biotechnology (VIR – Research Report) on January 13 and set a price target ...

Vir Biotechnology, Inc. (NASDAQ:VIR – Get Free Report)’s share price dropped 3.8% during trading on Friday . The stock traded as low as $10.81 and last traded at $10.78. Approximately 201,759 shares ...

Vir Biotechnology, Inc. (NASDAQ:VIR – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the six ...

SOUTH SAN FRANCISCO, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALLO), a clinical-stage biotechnology company ...

Vir Biotechnology Inc (VIR) stock saw a modest uptick, ending the day at $11.2 which represents a slight increase of $0.67 or 6.36% from the prior close of $10.53. The stock opened at $10.48 and ...

These initial results provide clinical support for Vir Biotechnology’s in-licensed PRO-XTEN™ masking technology, which is designed to enable the selective activation of TCEs in the tumor ...

Vir Biotechnology's recent share price rally is driven by their promising cancer program, despite their primary focus on hepatitis management. The company's market cap has surged past $1 billion ...

J.P. Morgan analyst Eric Joseph maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report) today and set a price target of $30.00.

Morgan Stanley upgrades Vir Biotechnology to Overweight with a $20 price target. Get Real-Time News and Alerts for Your Portfolio Data show encouraging preliminary safety and efficacy profiles ...

In this article, we are going to take a look at where Vir Biotechnology, Inc. (NASDAQ:VIR) stands against the other stocks that are skyrocketing now. The market has started to favor smaller ...